NCT Number: NCT00034801
Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
This is a research study comparing the safety and efficacy of two active study medications
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–60 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Primary location
Tuscaloosa, Alabama, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Male or female subjects 18-60 years of age
- Female subjects of childbearing potential must be using a medically accepted means of contraception
- Each subject must have a level of understanding sufficient to perform all tests and examinations required by the protocol
- Subjects must be considered reliable
Exclusion criteria
- Treatment with a drug within the last 30 days that has not received regulatory approval at the time of study entry
- Female subjects who are either pregnant or nursing
- Uncorrected hypothyroidism or hyperthyroidism
- Narrow-angle glaucoma
Treatment and study plan
Ziprasidone
DrugSponsors and collaborators
Lead sponsor
Eli Lilly and Company
Industry
Registry information
Official study title
A Controlled Trial of Olanzapine Versus Active Comparator in the Treatment of Schizophrenic and Schizoaffective Subjects With Comorbid Depression
Important dates
- Study start
- 2001
- Study completion
- 2003
- First posted
- May 3, 2002
- Registry last updated
- Jul 19, 2006
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME)
NCT01992393
Behavior, Behavioral Symptoms
Cleveland, Ohio, United States
View Trial DetailsSelf-Management Training and Automated Telehealth to Improve SMI Health Outcomes
NCT02188732
Behavior, Behavioral Symptoms
Boston, Massachusetts, United States
View Trial DetailsOpen-label Study of Curcumin C-3 Complex in Schizophrenia
NCT01875822
Behavior, Behavioral Symptoms
San Juan, Puerto Rico
View Trial DetailsEffectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder
NCT00316303
Behavior, Behavioral Symptoms
Baltimore, Maryland, United States
View Trial Details